TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Any Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 7 Days of Any Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Confirmed Chikungunya Virus (CHIKV) Infection Events
Endpoint domain: Adverse events/effects
Primary endpoint: Neuroendocrine function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients with Transthyretin (TTR) mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBC, platelet and differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BUN, creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: total bilirubin, alkaline phosphatase, LDH, SGPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The parameters of cross road
Endpoint domain: General outcomes
Primary endpoint: Risk of alcohol-exposed pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Yale Preoperative Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation of the period of the ventilatory cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in SICI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in ICF measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Resolution of Viral Conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf (area under the concentration curve to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Knee Society Score (AKSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma Cmax for bosutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt for bosutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUCinf for bosutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFNC treatment outcome (failure or success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse incidence
Endpoint domain: Mortality/survival
Primary endpoint: Health Care Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in polycystic ovary syndrome disease measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Global cardiac function (LV ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intention to Smoke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Fasting Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects Losing at Least 5% of Baseline Fasting Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Beginning of Substantial Relief of the Defining Symptom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fine wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Purpura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of acute pancreatitis post-ERCP
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Maternal Subjects With Any Solicited Administration Site Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Maternal Subjects With Any Solicited Systemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Maternal Subjects With Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe acute radioactive oral mucitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of CML to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GBS Disability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRC Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erasmus GBS Respiratory Insufficiency Score (EGRIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Erasmus GBS Outcome Score (EGOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Neuropathy Limitations Scale (ONLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life (EQ-5D Sum Score) at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life (EQ-5D Sum Score) at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life (Euroqol-5D Visual Analog) at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life (Euroqol-5D Visual Analog) at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life Scores (EACH-Q) at 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall completeness of reporting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recovery Time of T1 to 90% Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-time recorded claim for venous thrombosis or pulmonary embolism with hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: First-time recorded claim for ischemic stroke/hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: First-time recorded claim for acute myocardial infarction or acute coronary revascularization/hospitalized
Endpoint domain: Mortality/survival
Primary endpoint: Success in Physician's Global Assessment of Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in LDL-C: Mean of Weeks 10 and 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in sub-basal nerve density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in diameter of nerve branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in number of nerve branches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose-120 min OGTT-AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trans-Epidermal Water-Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation of cardiac output (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Complete Polyp Regression From Baseline at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in WOMAC Knee and Hip Osteoarthritis Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of take of thin skin autografts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The evolution of signs and symptoms of vaginitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of contaminated urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in TNF-alpha Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Thoracic CT imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUS results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait kinetic and kinematic parameters at the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PTSD Symptoms (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PDSS Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximally tolerated dose of oblimersen sodium
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Blood Components Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in WOMAC Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: YBOCS Obsessive-Compulsive Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement - Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dynamic elastacy ratio PPV/SVV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of aggrecansase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: amount of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itch Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Beck Depression Inventory - Second Edition (BDI-II) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Anxiety Inventory (BAI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pulmonary Function (Normalized FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RV to LV conduction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of bucking during the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Sponsor determined clinical cure of otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sponsor determined microbiological cure of otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change From Baseline in Maximal Aerobic Capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Aerobic Capacity-shuttle Test (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Time Taken for 40 Meter (m) Sprint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-hCG level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in SGRQ-C total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-Report Caregiver reported outcomes at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pulmonary health index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glycogen re-synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in drunkenness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in drowsiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Overactive Bladder (OAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of systemic error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of random error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 20% decline in creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in average dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prolonged mechanical ventilation (> 48h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Grade 2 Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders/Non-responders for Each STK11 rs8111699 Genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovulation Rate Over Study Duration for STK11 Genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Voluntary and electrically evoked forces on the contracted muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to specific treatment for final diagnosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Length of stay in the emergency department (ED)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ED and total hospital costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: changes in oxygen maximal consumption (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of c-Met/PD-L1 CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-24h of individual blood oleuropein metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Time To Progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to treatment recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Disability of the Army Shoulder Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of detected cases
Endpoint domain: Adverse events/effects
Primary endpoint: magnetic resonance images (structural and functional)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of ocular and nonocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ of Sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,max of Sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Reported Site Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Subject Discontinuations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mesh Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complete Resolution of Labial Adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective insertion and removal as measured by hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amount of effort required for both insertion and removal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUCi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Peak Expiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of Participants Who Developed Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to metastatic spread or local cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Mayo total wrist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of near-infrared technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional Autonomy Measurement System (SMAF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Pressure Sores
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of specific pattern of LDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Failing to Avoid Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to failure of strategy (TFS)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reproducibility of cephalometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of cancer-related mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Global improvement in gastrointestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Each participant's time in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean score of the Emotional Burden section of the Diabetes Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relapse Rate (local and/or distant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Tender and Swollen 28 Joint Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of Cognitive performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variability of motor performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of low dose ASA discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accurate topography of heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reporting arterial and venous anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reporting nervous structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Train of Four Ratio (TOF 0.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological Success (MITT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasitological Success (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Opioid Use Hour 0-24
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of cases with delivery within 7 days after admission
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of negative cultures after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Type-specific antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the drug-time curve (AUC0-2W)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug-time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug-time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potassium level in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes